Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04068610 · ClinicalTrials.gov registry record · Phase 1
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
A Phase 1 study of Metastatic Microsatellite-stable Colorectal Cancer, sponsored by MedImmune.
- Active
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 20
- Study locations
NCT04068610 is a Phase 1 study of Metastatic Microsatellite-stable Colorectal Cancer that is active but no longer recruiting, run by MedImmune. The registered enrollment target is 61 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT04068610, a Phase 1 study of Metastatic Microsatellite-stable Colorectal Cancer, is active but no longer recruiting, sponsored by MedImmune.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 20
- Study locations
Study Summary
COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC).
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Durvalumab
- DRUG FOLFOX
- DRUG Oleclumab
Study Locations (20)
Other
- Research Site - Clayton
- Research Site - Heidelberg
- Research Site - Melbourne
- Research Site - Nantes
- Research Site - Villejuif
- Research Site - Barcelona
- Research Site - Barcelona
- Research Site - Madrid
California
- Research Site - Los Angeles
- Research Site - Sacramento
Tennessee
- Research Site - Chattanooga
- Research Site - Nashville
Michigan
- Research Site - Ann Arbor
Nevada
- Research Site - Las Vegas
New York
- Research Site - New York
Ohio
- Research Site - Canton
Rhode Island
- Research Site - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-09-13 |
| Est. Completion | 2026-11-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04068610
The ClinicalTrials.gov registry entry for NCT04068610 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Microsatellite-stable Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT04068610 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04068610 about?
NCT04068610 is a clinical study titled "COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC". COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC).
What is the current status of trial NCT04068610?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2019-09-13. Estimated completion is 2026-11-24.
What conditions does trial NCT04068610 study?
This clinical trial studies the following conditions: Metastatic Microsatellite-stable Colorectal Cancer.
What interventions are being tested in trial NCT04068610?
The interventions under investigation include: Bevacizumab (DRUG), Durvalumab (DRUG), FOLFOX (DRUG), Oleclumab (DRUG).
Who is sponsoring clinical trial NCT04068610?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04068610 being conducted?
This trial has 20 study locations across California, Michigan, Nevada, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.